Back to Directory
Amprologix
Founded 2018
Antibiotics targeting drug-resistant bacterial infections
Amprologix is a biotechnology company developing antibiotics to tackle infections caused by drug-resistant bacteria. Its lead programme centres on epidermicin NI01, an antimicrobial protein being developed as a potential treatment for bacterial infections. Established in 2018 from University of Plymouth research, the company works with Ingenza on manufacturing development and is advancing its antibiotic programme through preclinical research towards clinical evaluation.